Search results for "Cardiotonic agents"

showing 10 items of 49 documents

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational an…

2018

Abstract Background The value of digoxin in heart failure (HF) remains controversial, particularly in patients with preserved ejection fraction (HFpEF). This study evaluated the 1-year risk of events after digoxin treatment for acute heart failure (AHF) in patients >70 years old with HFpEF. Methods 1833 patients were included in this analysis (mean age, 82 years). The main endpoints were all-cause death and the composite of death and/or HF re-admission within 1 year. Cox regression analysis was used to evaluate the association between digoxin treatment and prognosis. Results 401 patients received digoxin treatment; of these, 86% had atrial fibrillation. The mean baseline heart rate was 86 ±…

MaleDigoxinmedicine.medical_specialtyCardiotonic AgentsDigoxin030204 cardiovascular system & hematologyPatient Readmission03 medical and health sciences0302 clinical medicineOlder patientsHeart RateRisk FactorsCause of DeathInternal medicineAtrial FibrillationHeart rateInternal MedicinemedicineHumansProspective StudiesRegistries030212 general & internal medicineAgedProportional Hazards ModelsAged 80 and overHeart FailureEjection fractionProportional hazards modelbusiness.industryStroke VolumeAtrial fibrillationPrognosismedicine.diseasePatient DischargeSpainHeart failureMultivariate AnalysisCardiologyFemaleObservational studybusinessmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct

General oxidative stress during doxorubicin-induced cardiotoxicity in rats: Absence of cardioprotection and low antioxidant efficiency of alpha-lipoi…

2012

International audience; To evaluate the effects of alpha-lipoic acid (AL) in a model of doxorubicin (DOX)-induced cardiotoxicity, male Wistar rats were treated with DOX (1 mg/kg/d; 10 d) in combination or not with AL (50 mg/kg/d; 15 d). Plasma oxidative stress was determined by hydroperoxides (ROOH) and the ascorbyl radical/ascorbate ratio. One and two months later, the functional parameters of the hearts were determined in vivo by catheterization and cardiac oxidative stress was assessed by malonedialdehyde (MDA) and O₂*⁻ (dihydroethidium fluorescence) content in tissue. After two months, body weight was higher in the DOX-AL group than in DOX (+16%), but this was due to ascites. Histologic…

MaleMESH : Oxidative StressAntioxidantmedicine.medical_treatmentMESH : HematocritMESH : Thioctic AcidBiochemistryAntioxidants0302 clinical medicineSuperoxidesAscitic FluidMESH: AnimalsMESH : Body WeightComputingMilieux_MISCELLANEOUS0303 health sciencesThioctic AcidCumulative doseMESH: Heart DiseasesHeartGeneral Medicine3. Good healthMESH: Ascitic Fluid[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisMESH : Ascitic FluidMESH: Hydrogen PeroxideMESH : AntioxidantsMESH: Thioctic Acidmedicine.medical_specialtyCardiotonic AgentsCardiotoxinsMESH: Hematocrit03 medical and health sciencesMESH: Doxorubicin[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoRats Wistar[ SDV ] Life Sciences [q-bio]MyocardiumMESH: AntioxidantsHydrogen PeroxideMESH: Cardiotonic AgentsMESH : Organ SizeMESH: Body WeightMESH: Heartcarbohydrates (lipids)EndocrinologyMESH: LiverMESH : SuperoxidesMESH: Organ Size[SDV]Life Sciences [q-bio]MESH : Cardiotonic AgentsAscorbic AcidMESH: Superoxidesmedicine.disease_causeMESH: EatingEatingpolycyclic compoundsMESH : MyocardiumMESH: Thiobarbituric Acid Reactive SubstancesMESH: Ascorbic AcidAntibiotics AntineoplasticMESH: Oxidative StressChemistryMESH : RatsOrgan SizeMESH : Antibiotics Antineoplastic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBiochemistryHematocritLiverMESH : Cardiotoxinsmedicine.drugMESH : EatingMESH: MyocardiumHeart DiseasesMESH: RatsMESH : MaleMESH : Thiobarbituric Acid Reactive SubstancesMESH : Rats WistarThiobarbituric Acid Reactive SubstancesContractilityMESH : HeartInternal medicinemedicineTBARSAnimalsMESH : DoxorubicinDoxorubicinMESH: Antibiotics AntineoplasticMESH : Ascorbic Acid030304 developmental biologyCardiotoxicityBody WeightMESH : LiverMESH : Heart DiseasesMESH: Rats WistarMESH: MaleRatsOxidative StressMESH: CardiotoxinsDoxorubicinMESH : AnimalsMESH : Hydrogen PeroxideOxidative stress
researchProduct

Possible Reduction of Cardiac Risk after Supplementation with Epigallocatechin Gallate and Increase of Ketone Bodies in the Blood in Patients with Mu…

2020

Multiple sclerosis (MS) is a neurodegenerative disease that causes anthropometric changes characterised by functional disability, increase in fat mass, and decrease in lean mass. All these variables are related to a greater cardiac risk. The polyphenol epigallocatechin gallate (EGCG) and an increase in ketone bodies in the blood have been shown to have beneficial effects on anthropometric and biochemical variables related to cardiovascular activity. The aim of this study was to analyse the impact of the intervention with EGCG and ketone bodies on cardiac risk in MS patients. A population of 51 MS patients were randomly assigned to a control group and an intervention group (daily dose of 800…

MalePilot ProjectsKetone Bodies030204 cardiovascular system & hematologyEpigallocatechin gallatemultiple sclerosisCatechinBody Mass Indexchemistry.chemical_compound0302 clinical medicineFunctional abilityeducation.field_of_studyNutrition and Dieteticsbiology3-Hydroxybutyric AcidAnthropometryfood and beveragesMiddle AgedPON1C-Reactive ProteinTreatment OutcomeCardiovascular DiseasesKetone bodiesFemalelcsh:Nutrition. Foods and food supplyAdultmedicine.medical_specialtycardiac riskepigallocatechin gallateWaistCardiotonic AgentsMultiple SclerosisPopulationlcsh:TX341-641Article03 medical and health sciencesInternal medicinemedicineHumanseducationSerum AlbuminAnalysis of VarianceWaist-Height Ratiobusiness.industryAryldialkylphosphataseParaoxonaseEndocrinologychemistryHeart Disease Risk FactorsDietary Supplementsketone bodiesLean body massbiology.proteinbusiness030217 neurology & neurosurgeryFood Science
researchProduct

Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwentsurgical reperfusion: a randomized double-…

2007

Background: The inflammatory cascade has been hypothesized to be an important mechanism of post-ischaemic myocardial reperfusion injury and several studies demonstrated that C1 esterase inhibitor (C1 -INH) is effective in post-ischaemia myocardial protection. Therefore, we aimed to investigate prospectively in a randomised double-blind study the cardioprotective effects of C1-INH in ST segment elevation myocardial infarction (STEMI) in patients who underwent emergent reperfusion with coronary artery bypass grafting (CABG). Methods: In this study, we enrolled 80 patients affected with STEMI who underwent emergent CABG. Patients were assigned in two groups (C1-INH group: receive 1000 Ul of C1…

MalePulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyMean arterial pressureCardiotonic AgentsMyocardial InfarctionCardiac indexMyocardial ReperfusionComplement C1 Inactivator ProteinsCoronary artery bypass surgeryReperfusion therapyDouble-Blind MethodInternal medicinemedicineHumansProspective StudiesMyocardial infarctionCoronary Artery BypassInfusions IntravenousSTEMI patients CABG C1 esterase inhibitor Reperfusion injury Complement cascade Myocardial function recoverybusiness.industryST elevationTroponin IComplement C4aGeneral MedicineMiddle Agedmedicine.diseaseMyocardial ContractionComplement Inactivating AgentsTreatment OutcomeComplement C3aCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessReperfusion injury
researchProduct

Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.

2009

Purpose. To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines. Methods. The study, double-blinded, randomised, assessed intravenous infusion of LPC 1.2 g/day in combination with PGE-1, 60 mg/day (LPC group: 37 patients), or PGE-1 only (control group: 38 patients) in a total of 75 patients suffering from CLI. Treatment duration was 20 days. We evaluated rest pain, maximum walking distance (MWD) and skin ulcer size. Results. In both groups we observed a significant reduction in pain score and ulcer size and an increase in MWD. In the patients treated with the combination, the improvement was greater…

MaleSettore MED/09 - Medicina InternaCardiotonic AgentsVasodilator AgentsProstaglandin E1IschemiaPainWalkinglaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawIschemiaCarnitinemedicineHumansPharmacology (medical)CarnitineAlprostadilProstaglandin E1Infusions IntravenousAgedPharmacologyLegCritical Limb Ischemiabusiness.industryTherapeutic effectLeg UlcerDrug SynergismGeneral MedicineCritical limb ischemiaL-PropionylcarnitineSkin ulcerMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment OutcomechemistryAnesthesiaChronic Diseaselipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicineClaudicationbusinessmedicine.drugCardiovascular drugs and therapy
researchProduct

Docosahexaenoic acid, but not eicosapentaenoic acid, lowers ambulatory blood pressure and shortens interval QT in spontaneously hypertensive rats in …

2009

International audience; This study was designed to evaluate the effects of individual dietary long-chain n-3 polyunsaturated fatty acids (LCPUFA) on hypertension and cardiac consecutive disorders in spontaneously hypertensive rats (SHR) as compared to Wistar-Kyoto rats (WKY). Rats were fed for 2 months an eicosapentaenoic (EPA)- or docosahexaenoic acid (DHA)-rich diet (240 mg/day) or an n-3 PUFA-free diet. Male SHR (n=6), implanted with cardiovascular telemetry devices, were housed in individual cages for continuous measurements of cardiovascular parameters (blood pressure (BP) and heart rate (HR)) during either activity or rest periods, ECG were recorded during the quiet period. The n-6 PU…

MaleecgClinical BiochemistryBlood Pressure030204 cardiovascular system & hematologyEssential hypertensionRats Inbred WKYElectrocardiographychemistry.chemical_compound0302 clinical medicineRats Inbred SHRmembrane2. Zero hungerchemistry.chemical_classification0303 health sciences[SDV.BA]Life Sciences [q-bio]/Animal biologytelemetryEicosapentaenoic acid3. Good healthshrEicosapentaenoic AcidDocosahexaenoic acidHypertensioncardiovascular systemArachidonic acidlipids (amino acids peptides and proteins)Polyunsaturated fatty aciddietary n-3 lcpufamedicine.medical_specialtyCardiotonic AgentsDocosahexaenoic AcidsLinoleic acidheartBiology03 medical and health sciencesFatty Acids Omega-6Internal medicinemedicineAnimalsUnsaturated fatty acidphospholipid030304 developmental biologyMyocardiumessential hypertensionCell Biologymedicine.diseaseRatsblood pressure monitoringEndocrinologyBlood pressurechemistryEndothelium Vascular[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.

2010

Abstract Background and aims The anorexigenic glucagon-like peptide (GLP)-2 is produced by intestinal L cells and released in response to food intake. It affects intestinal function involving G-protein-coupled receptors. To verify whether GLP-2 acts as a cardiac modulator in mammals, we analysed, in the rat heart, the expression of GLP-2 receptors and the myocardial and coronary responses to GLP-2. Methods and results GLP-2 receptors were detected on ventricular extracts by quantitative real-time polymerase chain reaction (Q-RT-PCR) and Western blotting. Cardiac GLP-2 effects were analysed on Langendorff perfused hearts. Intracellular GLP-2 signalling was investigated on Langendorff perfuse…

Maleendocrine systemmedicine.medical_specialtyCardiotonic AgentsNitric Oxide Synthase Type IIIMAP Kinase Signaling SystemG proteinEndocrinology Diabetes and MetabolismBlotting WesternMedicine (miscellaneous)Enzyme-Linked Immunosorbent AssayStimulationIn Vitro TechniquesBiologyReal-Time Polymerase Chain Reactionglucagon-like peptides-2 gut peptides cardiac performanceSettore BIO/09 - FisiologiaGlucagon-Like Peptide-1 Receptorchemistry.chemical_compoundInternal medicineCyclic AMPCyclic GMP-Dependent Protein KinasesGlucagon-Like Peptide 2Receptors GlucagonmedicineAnimalsCyclic adenosine monophosphatePhosphorylationRats WistarReceptorNutrition and Dieteticsdigestive oral and skin physiologyHeartPeptide FragmentsRatsPhospholambanEndocrinologyGene Expression RegulationchemistryInotropismGlucagon-Like Peptide-2 ReceptorCardiology and Cardiovascular MedicinecGMP-dependent protein kinasehormones hormone substitutes and hormone antagonistsIntestinal L CellsSignal Transduction
researchProduct

Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings.

2019

Abstract Background There are reports of the familial occurrence of Kawasaki disease but only a few reports described Kawasaki disease in siblings. However, the familial cases were not simultaneous. In these patients the idea of infective agents as trigger must be considered. Case presentation We describe two siblings with atypical presentations of Kawasaki disease; the sister was first diagnosed as having parvovirus infection with anemia and the brother was diagnosed as having myocarditis. The first patient was a 9-month-old Caucasian girl with fever, conjunctivitis, rash, and pharyngitis, and later she had cervical adenopathy, diarrhea and vomiting, leukocytosis, and anemia, which were ex…

Malemedicine.medical_specialtyAbdominal painViral MyocarditisMyocarditisCardiotonic AgentsDopaminelcsh:MedicineCase Report030204 cardiovascular system & hematologyGastroenterologyParvoviridae InfectionsParvovirus03 medical and health sciences0302 clinical medicineInternal medicineDobutaminemedicineHumansImmunologic FactorsLeukocytosisChildKawasaki diseasebusiness.industryMedicine (all)Siblingslcsh:RParvovirus infectionCoronary AneurysmInfantShockStroke VolumeGeneral MedicineKawasaki shock syndromemedicine.diseasePharyngitisInterleukin 1 Receptor Antagonist ProteinTreatment OutcomeAnakinraEchocardiography030220 oncology & carcinogenesisAnuriaKawasaki diseaseFemalemedicine.symptombusinessImmunosuppressive AgentsJournal of medical case reports
researchProduct